Evidence map›Paper›PMID 35260892›Full record

ReviewClinical science (London, England : 1979)2022

Renal mitochondrial injury in the pathogenesis of CKD: mtDNA and mitomiRs.

Maria V Irazabal, Alejandro R Chade, Alfonso Eirin

Open access · greenAbstract readReview
In one paragraph

Review in Clinical science (London, England : 1979), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. The Role of Mitochondria in Polycystic Kidney Disease.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells.Journal of the American Society of Nephrology : JASN · 2024
    Article
  10. Role of mitochondria in endogenous renal repair.Clinical science (London, England : 1979) · 2024
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Maria V IrazabalDepartment of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, U.S.A.
Alejandro R ChadeDepartment of Physiology and Biophysics, Medicine, and Radiology, University of Mississippi Medical Center, Jackson, MS, U.S.A.
Alfonso EirinDepartment of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, U.S.A.ORCID 0000-0002-3864-9644
Mayo Clinic · USUniversity of Mississippi Medical Center · US

Funding

The role of leptin in autoimmune-associated hypertensionP20GM104357 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI TAYLOR, ERIN BASSFORD · 2013 to 2022
$23.4M
Microcirculation in Renovascular HypertensionR01HL095638 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHADE, ALEJANDRO ROBERTO · 2010 to 2021
$3.9M
Role of homocysteine metabolism, endothelial function and microvascular rarefaction on renal disease severity and progression in ADPKDR01DK128017 · NIDDK · MAYO CLINIC ROCHESTER · PI IRAZABAL, MARIA V · 2021 to 2024
$2.4M
Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repairR01DK129240 · NIDDK · MAYO CLINIC ROCHESTER · PI Alfonso Eirin · 2023 to 2026
$1.8M
Noninvasive assessment of renal fibrosis using magnetization transfer MRIU01DK104273 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2014 to 2018
$1.8M
Role of Fumarate and Nrf2 response in the pathogenesis of Autosomal Dominant Polycystic Kidney DiseaseR21DK118391 · NIDDK · MAYO CLINIC ROCHESTER · PI IRAZABAL, MARIA V · 2018 to 2020
$586k
Role of NOX4 and redox environment in Autosomal Dominant Polycystic Kidney DiseaseR56DK126700 · NIDDK · MAYO CLINIC ROCHESTER · PI IRAZABAL, MARIA V · 2020 to 2020
$100k
Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repairR56DK129240 · NIDDK · MAYO CLINIC ROCHESTER · PI EIRIN, ALFONSO · 2021 to 2021
$100k
NHLBI NIH HHS R01 HL095638NIDDK NIH HHS R01 DK128017NIDDK NIH HHS R01 DK129240NIDDK NIH HHS R21 DK118391NIDDK NIH HHS R56 DK126700NIDDK NIH HHS R56 DK129240NIDDK NIH HHS U01 DK104273NIGMS NIH HHS P20 GM104357
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a public health concern that affects over 200 million people worldwide and is associated with a tremendous economic burden. Therefore, deciphering the mechanisms underpinning CKD is crucial to decelerate its progression towards end-stage renal disease (ESRD). Renal tubular cells are populated with a high number of mitochondria, which produce cellular energy and modulate several important cellular processes, including generation of reactive oxygen species (ROS), calcium homeostasis, proliferation, and apoptosis. Over the past few years, increasing evidence has implicated renal mitochondrial damage in the pathogenesis of common etiologies of CKD, such as diabetes, hypertension, metabolic syndrome (MetS), chronic renal ischemia, and polycystic kidney disease (PKD). However, most compelling evidence is based on preclinical studies because renal biopsies are not routinely performed in many patients with CKD. Previous studies have shown that urinary mitochondrial DNA (mtDNA) copy numbers may serve as non-invasive biomarkers of renal mitochondrial dysfunction. Emerging data also suggest that CKD is associated with altered expression of mitochondria-related microRNAs (mitomiRs), which localize in mitochondria and regulate the expression of mtDNA and nucleus-encoded mitochondrial genes. This review summarizes relevant evidence regarding the involvement of renal mitochondrial injury and dysfunction in frequent forms of CKD. We further provide an overview of non-invasive biomarkers and potential mechanisms of renal mitochondrial damage, especially focusing on mtDNA and mitomiRs.

Indexed as

DNA, MitochondrialRenal Insufficiency, ChronicBiomarkersFemaleHumansKidneyMaleMitochondriaBiomarkersDNA, MitochondrialChronic kidney diseaseMetabolic syndromemicroRNAMitochondriamtDNAPKD

Identifiers

PMID35260892
PMCPMC10018514
OpenAlexW4220761981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.